Illumina Future Growth

Future criteria checks 4/6

Illumina is forecast to grow earnings and revenue by 68.5% and 7.7% per annum respectively. EPS is expected to grow by 68.8% per annum. Return on equity is forecast to be 9% in 3 years.

Key information

68.5%

Earnings growth rate

68.8%

EPS growth rate

Life Sciences earnings growth	0%
Revenue growth rate	7.7%
Future return on equity	9.0%
Analyst coverage	Good
Last updated	09 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BOVESPA:I1LM34 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	5,432	523	1,032	975	11
12/31/2025	4,989	253	760	958	18
12/31/2024	4,519	-115	529	388	18
12/31/2023	4,504	-1,161	282	478	N/A
10/1/2023	4,465	-1,125	168	401	N/A
7/2/2023	4,461	-4,186	-224	210	N/A
4/2/2023	4,448	-4,487	-228	230	N/A
1/1/2023	4,584	-4,404	-74	392	N/A
10/2/2022	4,700	-4,153	79	527	N/A
7/3/2022	4,693	-20	53	307	N/A
4/3/2022	4,656	701	208	435	N/A
1/2/2022	4,526	762	337	545	N/A
10/3/2021	4,280	907	469	669	N/A
7/4/2021	3,966	769	898	1,094	N/A
4/4/2021	3,473	630	890	1,081	N/A
1/3/2021	3,239	656	891	1,080	N/A
9/27/2020	3,238	638	933	1,117	N/A
6/28/2020	3,351	693	1,046	1,231	N/A
3/29/2020	3,556	942	941	1,134	N/A
12/29/2019	3,543	1,002	842	1,051	N/A
9/29/2019	3,458	973	691	908	N/A
6/30/2019	3,405	938	701	933	N/A
3/31/2019	3,397	851	823	1,085	N/A
12/30/2018	3,333	826	846	1,142	N/A
9/30/2018	3,243	684	829	1,136	N/A
7/1/2018	3,103	648	752	1,079	N/A
4/1/2018	2,936	567	643	962	N/A
12/31/2017	2,752	725	563	875	N/A
10/1/2017	2,594	775	N/A	843	N/A
7/2/2017	2,487	741	N/A	784	N/A
4/2/2017	2,424	730	N/A	848	N/A
1/1/2017	2,398	454	N/A	779	N/A
10/2/2016	2,371	440	N/A	757	N/A
7/3/2016	2,314	430	N/A	762	N/A
4/3/2016	2,253	415	N/A	692	N/A
1/3/2016	2,220	462	N/A	786	N/A
9/27/2015	2,141	510	N/A	560	N/A
6/28/2015	2,071	486	N/A	524	N/A
3/29/2015	1,979	430	N/A	531	N/A
12/28/2014	1,861	353	N/A	501	N/A
9/28/2014	1,736	281	N/A	488	N/A
6/29/2014	1,612	219	N/A	425	N/A
3/30/2014	1,511	208	N/A	336	N/A
12/29/2013	1,421	125	N/A	386	N/A
9/29/2013	1,343	117	N/A	338	N/A
6/30/2013	1,272	115	N/A	307	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: I1LM34 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (9.8%).

Earnings vs Market: I1LM34 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: I1LM34 is expected to become profitable in the next 3 years.

Revenue vs Market: I1LM34's revenue (7.7% per year) is forecast to grow faster than the BR market (7.3% per year).

High Growth Revenue: I1LM34's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: I1LM34's Return on Equity is forecast to be low in 3 years time (9%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Illumina Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Recent updates

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Illumina, Inc. Announces CEO Changes

Illumina, Inc. Announces Board Changes

Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients

Illumina, Inc. Announces Board Changes

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Appoints Joydeep Goswami as Chief Financial Officer

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022

Illumina Intends to Appeal EC's Decision in Grail Deal

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

Illumina, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Illumina, Inc.(NasdaqGS:ILMN) dropped from Russell 1000 Growth-Defensive Index

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions

Illumina, Inc. Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina, Inc., Annual General Meeting, May 26, 2022

John Frank Joins Illumina as Chief Public Affairs Officer

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Illumina, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Illumina, Inc. Supports Norway's Pioneering Precision Medicine Study

Randomized Trial Demonstrates Whole-Genome Sequencing Leads to Precision Care for Critically Ill Infants

Illumina, Inc. (NasdaqGS:ILMN) completed the acquisition of remaining 85.5% stake in GRAIL, Inc.

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Illumina, Inc. Supports Nationwide Program Across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis

Illumina, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of Fiscal 2021

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Illumina Announces Board Changes

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia

Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

Illumina, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Illumina, Inc. Wins Patent Infringement Suit Against BGI in the UK

Illumina, Inc. Announces the Launch of Illumina Connected Analytics

Kura Oncology, Inc., enters into A Master Collaboration Agreement with Illumina, Inc

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

Emedgene Collaborates with Illumina to Scale the Interpretation of Genomic Data for Rare Diseases

Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

Twist Bioscience Corporation, Illumina, Inc. and Western Digital Corporation Form Alliance with Microsoft to Advance Data Storage in DNA

Illumina, Inc. to Report Q3, 2020 Results on Oct 29, 2020

Illumina, Inc. (NasdaqGS:ILMN) acquired Enancio.

Illumina Reportedly in Talks to Buy Cancer Testing Startup Grail

Illumina, Inc. Announces Withdraw its Fiscal Full Year 2020

Illumina, Inc. to Report Q2, 2020 Results on Aug 06, 2020